Serum free light-chain assay for nonsecretory multiple myeloma with light chain cast nephropathy and light chain deposition disease

DOI Web Site 8 References
  • HONMA Riko
    Department of Medicine, Yamagata Prefectural Central Hospital
  • FUKASE Sachiko
    Department of Medicine, Yamagata Prefectural Central Hospital
  • SUZUKI Masayuki
    Department of Medicine, Yamagata Prefectural Central Hospital
  • OMOTO Eijiro
    Department of Medicine, Yamagata Prefectural Central Hospital

Bibliographic Information

Other Title
  • 血清遊離軽鎖定量により治療効果を判定した軽鎖円柱腎症と軽鎖沈着腎症を伴う非分泌型多発性骨髄腫
  • 症例報告 血清遊離軽鎖定量により治療効果を判定した軽鎖円柱腎症と軽鎖沈着腎症を伴う非分泌型多発性骨髄踵
  • ショウレイ ホウコク ケッセイ ユウリ ケイサ テイリョウ ニ ヨリ チリョウ コウカ オ ハンテイ シタ ケイサ エンチュウジンショウ ト ケイサ チンチャクジンショウ オ トモナウ ヒブンピツガタ タハツセイ コツズイショウ

Search this article

Description

Quantitative assay for serum free light chains (sFLC) is reported as a useful test for diagnosis and monitoring of patients with nonsecretory multiple myeloma (NSM). We performed serial sFLC assays in a patient with NSM with light chain cast nephropathy (LCCN) and light chain deposition disease (LCDD). After 3 cycles of VAD induction therapy, while plasma cells in the marrow decreased from 93.0% to 0.2%, sFLCκ/λ ratio remained abnormal. Flow cytometry assay also showed that these plasma cells were CD19 negative. After the subsequent high dose melphalan therapy followed by autologous peripheral blood stem cell transplantation (PBSCT), the sFLCκ/λ ratio returned to normal and the patient achieved a stringent complete response (sCR). One year after PBSCT, the patient remained in sCR with improved renal function. The quantitative FLC assay was useful for the diagnosis and monitoring of NSM and LCDD in this patient.

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 51 (4), 270-274, 2010

    The Japanese Society of Hematology

References(8)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top